ATE395063T1 - Pyridlsulfonamidopyrimidine zur behandlung von diabetischer nephropathie - Google Patents

Pyridlsulfonamidopyrimidine zur behandlung von diabetischer nephropathie

Info

Publication number
ATE395063T1
ATE395063T1 AT04716605T AT04716605T ATE395063T1 AT E395063 T1 ATE395063 T1 AT E395063T1 AT 04716605 T AT04716605 T AT 04716605T AT 04716605 T AT04716605 T AT 04716605T AT E395063 T1 ATE395063 T1 AT E395063T1
Authority
AT
Austria
Prior art keywords
treatment
diabetic nephropathy
pyridlsulfonamidopyrimidines
zero
8alkenyl
Prior art date
Application number
AT04716605T
Other languages
English (en)
Inventor
Jessica Mann
Original Assignee
Speedel Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Pharma Ag filed Critical Speedel Pharma Ag
Application granted granted Critical
Publication of ATE395063T1 publication Critical patent/ATE395063T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT04716605T 2003-03-06 2004-03-03 Pyridlsulfonamidopyrimidine zur behandlung von diabetischer nephropathie ATE395063T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03100549A EP1454625A1 (de) 2003-03-06 2003-03-06 Pyridylsulfonamidyl-pyrimidine zur Behandlung von diabetischen nephropathien

Publications (1)

Publication Number Publication Date
ATE395063T1 true ATE395063T1 (de) 2008-05-15

Family

ID=32799012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04716605T ATE395063T1 (de) 2003-03-06 2004-03-03 Pyridlsulfonamidopyrimidine zur behandlung von diabetischer nephropathie

Country Status (27)

Country Link
US (2) US20060094731A1 (de)
EP (2) EP1454625A1 (de)
JP (1) JP4737686B2 (de)
KR (1) KR101099189B1 (de)
CN (1) CN100453081C (de)
AT (1) ATE395063T1 (de)
AU (2) AU2004216858B2 (de)
BR (1) BRPI0408082A (de)
CA (1) CA2517930C (de)
CY (1) CY1108241T1 (de)
DE (1) DE602004013734D1 (de)
DK (1) DK1601361T3 (de)
EC (1) ECSP056060A (de)
ES (1) ES2305737T3 (de)
HK (1) HK1083761A1 (de)
HR (1) HRP20050860A2 (de)
IL (1) IL170626A (de)
MX (1) MXPA05009478A (de)
NO (1) NO20054148L (de)
NZ (1) NZ542155A (de)
PL (1) PL1601361T3 (de)
PT (1) PT1601361E (de)
RS (1) RS20050683A (de)
SI (1) SI1601361T1 (de)
UA (1) UA82087C2 (de)
WO (1) WO2004078104A2 (de)
ZA (1) ZA200507122B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595880A1 (de) * 2004-05-13 2005-11-16 Speedel Pharma AG Kristallforme eines Pyridinylsulfonamids und deren Verwendung als Endothelinrezeptorantagonisten
EP1924325A2 (de) * 2005-09-12 2008-05-28 Speedel Pharma AG Pyridylsulfonamidyl-pyrimidine zur prävention von blutgefäss-stützen-versagen
ES2712086T3 (es) 2010-06-17 2019-05-09 Nitto Denko Corp Agente para tratar la fibrosis renal
CN109260164A (zh) * 2018-10-07 2019-01-25 威海贯标信息科技有限公司 一种阿伏生坦片剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76542A (en) * 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
DE69626986T2 (de) * 1995-08-02 2004-02-05 Smithkline Beecham Corp. Endothelinrezeptorantagonist
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
WO2001081335A1 (en) * 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity

Also Published As

Publication number Publication date
ECSP056060A (es) 2006-01-27
CY1108241T1 (el) 2013-09-04
AU2004216858A1 (en) 2004-09-16
MXPA05009478A (es) 2005-10-18
AU2004216858B2 (en) 2009-07-16
JP4737686B2 (ja) 2011-08-03
AU2009225323A1 (en) 2009-11-05
ZA200507122B (en) 2006-05-31
ES2305737T3 (es) 2008-11-01
EP1454625A1 (de) 2004-09-08
HK1083761A1 (en) 2006-07-14
HRP20050860A2 (en) 2005-10-31
CA2517930A1 (en) 2004-09-16
DK1601361T3 (da) 2008-08-25
EP1601361A2 (de) 2005-12-07
NZ542155A (en) 2008-09-26
US20090005404A1 (en) 2009-01-01
CA2517930C (en) 2011-04-26
DE602004013734D1 (de) 2008-06-26
BRPI0408082A (pt) 2006-02-14
AU2009225323B2 (en) 2011-11-24
WO2004078104A3 (en) 2004-10-28
CN100453081C (zh) 2009-01-21
KR20050106083A (ko) 2005-11-08
IL170626A (en) 2010-05-31
EP1601361B1 (de) 2008-05-14
CN1756552A (zh) 2006-04-05
UA82087C2 (uk) 2008-03-11
PT1601361E (pt) 2008-07-29
JP2006519817A (ja) 2006-08-31
PL1601361T3 (pl) 2008-10-31
US20060094731A1 (en) 2006-05-04
SI1601361T1 (sl) 2008-10-31
KR101099189B1 (ko) 2011-12-27
RS20050683A (en) 2007-11-15
WO2004078104A2 (en) 2004-09-16
NO20054148L (no) 2005-09-06

Similar Documents

Publication Publication Date Title
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
DE60330757D1 (de) Verwendung von pyridylamiden als angiogenesehemmer
DK1855677T3 (da) 3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoser
DK1613304T3 (da) DPP-IV-inhibitorer
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
ATE540928T1 (de) Isochinolinverbindungen und ihre medizinische verwendung
ATE368031T1 (de) Neue gamma secretase inhibitoren
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
ATE537152T1 (de) Verbindungen, ihre pharmazeutischen zusammensetzungen und ihre verwendung in der behandlung von stoffwechselstörungen
ATE553077T1 (de) Peptidaseinhibitoren
DE602005010421D1 (de) Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
NO20054148L (no) Nytt medikament
GB0412314D0 (en) Compounds
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.
ATE485820T1 (de) Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie
DK1499312T3 (da) Anvendelse af hydroxypyridonderivater til sårheling
ATE338046T1 (de) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität
DE60214558D1 (de) 2-(AMINOMETHYL)TETRAHYDRO-9-OXA-1,3-DIAZACYCLOPENTAcAÜNAPHTHALINYLDERIVATE MIT ANTIPSYCHOTISCHER WIRKUNG
NO20051468L (no) Behandling av ikke-allergisk rhinitt med selektive fosfodiesterase-4-inhibitorer
TH82384A (th) อนุพันธ์แอริล 1,4-ไพราซินที่ถูกแทนที่
TH76971A (th) อนุพันธ์ไตรไซคลิกที่ถูกหลอม
TH77763A (th) ไบไซคลิค-6-อัลคิลิดีน-พีเนมเป็นตัวยับยั้ง เบตา-แลคแตมเมส

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1601361

Country of ref document: EP